Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 12 newly hired employees under Nasdaq Listing Rule 5635(c)(4), pursuant to the company’s 2024 Inducement Stock Incentive Plan. The grants comprise non-statutory stock options for up to an aggregate 358,600 common shares and restricted stock units (RSUs) covering 116,500 shares.
The stock options have a ten-year term and are scheduled to vest over four years: 25% on the first anniversary of each employee’s start date, with the balance vesting in 12 equal quarterly installments, subject to continued service. The RSUs are scheduled to vest in four equal annual installments over four years from each employee’s start date, also subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
News ID 1083720 was followed by a -1.22% 24-hour reaction despite positive FDA acceptance. Against t...
Analysis
News ID 1083720 was followed by a -1.22% 24-hour reaction despite positive FDA acceptance. Against that record, the employee-award announcement remains informational, with net selling as a sourced risk factor.
Key Figures
New hires receiving awards:12 employeesStock options:358,600 sharesRestricted stock units:116,500 shares+5 more
8 metrics
New hires receiving awards12 employeesInducement equity awards
Stock options358,600 sharesAggregate shares subject to options
Restricted stock units116,500 sharesAggregate shares subject to RSUs
Option termTen yearsNon-statutory stock options
Initial option vesting25%Vests on the first employee anniversary
Option vesting installments12 installmentsEqual quarterly installments after initial vesting
Option vesting periodFour yearsScheduled option vesting period
RSU vesting installmentsFour installmentsEqual annual installments over four years
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent offering announcements aligned with negative reactions, while positive regulatory and management news diverged; a prior inducement-grant announcement was followed by a positive reaction.
"The inducement equity awards consisted of non-statutory stock options"
Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.
restricted stock unitsfinancial
"and restricted stock units with respect to an aggregate of 116,500 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 12 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 358,600 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on July 21, 2026, and restricted stock units with respect to an aggregate of 116,500 shares of Dyne’s common stock.The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates.The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.
The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts: Investors Mia Tobias ir@dyne-tx.com 781-317-0353
What inducement equity awards did Dyne Therapeutics (DYN) grant on July 24, 2026?
Dyne Therapeutics granted non-statutory stock options for 358,600 shares and RSUs for 116,500 shares to 12 new hires. According to Dyne Therapeutics, these awards were issued as inducement grants under its 2024 Inducement Stock Incentive Plan and Nasdaq Listing Rule 5635(c)(4).
How do the Dyne Therapeutics (DYN) inducement stock options vest for new employees?
Dyne Therapeutics’ inducement stock options vest over four years, with 25% after one year and the remainder quarterly. According to Dyne Therapeutics, the remaining 75% vest in 12 equal quarterly installments, contingent on each employee’s continued service through the applicable vesting dates.
What are the vesting terms for Dyne Therapeutics (DYN) inducement RSUs granted in 2026?
Dyne Therapeutics’ inducement restricted stock units vest over four years in four equal annual installments. According to Dyne Therapeutics, vesting begins from each employee’s start date and remains subject to the employee’s continued service through the scheduled vesting dates.
At what price were Dyne Therapeutics (DYN) inducement stock options granted in July 2026?
Dyne Therapeutics granted inducement stock options with an exercise price equal to its July 21, 2026 closing share price. According to Dyne Therapeutics, this price reflects the closing price of DYN common stock on The Nasdaq Global Select Market on that date.
Why did Dyne Therapeutics (DYN) use Nasdaq Listing Rule 5635(c)(4) for these equity grants?
Dyne Therapeutics used Nasdaq Listing Rule 5635(c)(4) to grant equity awards as a material inducement to new hires. According to Dyne Therapeutics, these grants support employee recruitment and are issued under the company’s 2024 Inducement Stock Incentive Plan and related award agreements.
